Copyright
©The Author(s) 2022.
World J Gastroenterol. Oct 14, 2022; 28(38): 5626-5635
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5626
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5626
Clinicopathological features | HR (95%CI) | P value |
Sex | ||
Male | Reference | |
Female | 0.390 (0.076-1.988) | P = 0.257 |
Smoking history | ||
Yes | Reference | |
No | 0.725 (0.308-1.710) | P = 0.463 |
Family history of gastric cancer | ||
Yes | Reference | |
No | 0.495 (0.058-4.224) | P = 0.521 |
BMI | ||
18.5-23.9 | Reference | |
> 23.9 or < 18.5 | 1.848 (0.760-4.490) | P = 0.175 |
Postoperative hospital stay | ||
≤ 14 d | Reference | |
> 14 d | 1.198 (0.350-4.100) | P = 0.960 |
Tumor site | ||
Cardia cancer | Reference | |
Non-cardia gastric cancer | 0.620 (0.277-1.390) | P = 0.246 |
The degree of differentiation | ||
Poorly differentiated | Reference | |
Moderately differentiated | 0.517 (0.206-1.300) | P = 0.161 |
Highly differentiated | 0.390 (0.077-1.960) | P = 0.305 |
Vascular invasion | ||
Yes | Reference | |
No | 0.106 (0.045-0.246) | P < 0.001 |
- Citation: Xu Q, Kang WZ, Xiong JP, Shao XX, Li WK, Hu HT, Tian YT. A new scoring system to evaluate adjuvant chemotherapy for patients with T2N0M0 gastric cancer after D2 gastrectomy. World J Gastroenterol 2022; 28(38): 5626-5635
- URL: https://www.wjgnet.com/1007-9327/full/v28/i38/5626.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i38.5626